Dr. Reddy's Labs

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

HYDERABAD, India--( BUSINESS WIRE )--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy's”), a global pharmaceutical company, announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase 1 study. This Phase 1 study used a subcutaneous formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of Dr. Reddy's tocilizumab biosimilar candidate in comparison to reference products.

Dr. Reddy's Successfully Completes Phase 1 Study of DRL_TC, a Proposed Biosimilar of Tocilizumab

Amphastar Pharma

Sol-Gel Technologies

The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.

3 Generic Drug Stocks to Watch Amid Inflation Pressures

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Doctor Reddy's (RDY) is a Top-Ranked Momentum Stock: Should You Buy?

Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2023 Earnings Conference Call October 28, 2022 9:00 AM ET Company Participants Amit Agarwal - Head of Investor Relations & Director of Finance Parag Agarwal - Chief Financial Officer Erez Israeli - Chief Executive Officer Conference Call Participants Tarang Agarwal - Old Bridge Capital Prakash Agarwal - Axis Capital Kunal Dhamesha - Macquarie Capital Damayanti Kerai - HSBC Surya Patra - Philip Capital Operator Ladies and gentlemen, good day, and welcome to Q2 FY '23 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes.

Dr. Reddy's Laboratories Limited (RDY) Q2 2023 Earnings Call Transcript

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #4IR--World Economic Forum recognises Dr. Reddy's Hyderabad factory as part of its Global Lighthouse Network.

World Economic Forum Recognises Dr. Reddy's Hyderabad Factory as Part of its Global Lighthouse Network

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Doctor Reddy's (RDY) is a Top-Ranked Value Stock: Should You Buy?

Teva Pharmaceutical

The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.

3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Affordablemedicines--Dr. Reddy's Laboratories Ltd. today announced the launch, in the U.S. market, of Lenalidomide Capsules.

Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity

Bayer AG

GlaxoSmithKline

The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.

Plaintiff in first Zantac lawsuit set for trial drops case

Doctor Reddy's (RDY) is a Top-Ranked Growth Stock: Should You Buy?

Dr. Reddy's has launched multiple drugs in the US market recently which are expected to drive significant growth. The launch of bortezomib drug to give the company access to $1.2 billion myeloma treatment market.

Dr. Reddy's Laboratories: Multiple Drug Launches To Drive Significant Growth

Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q1 2023 Earnings Conference Call July 28, 2022 9:00 AM ET Company Participants Amit Agarwal - Head of Investor Relations and Director of Finance Parag Agarwal - Chief Financial Officer Erez Israeli - Chief Executive Officer Conference Call Participants Saion Mukherjee - Nomura Anubhav Aggarwal - Credit Suisse Damayanti Kerai - HSBC Prakash Agarwal - Axis Capital Neha Manpuria - Bank of America Sameer Baisiwala - Morgan Stanley Surya Patra - Philip Capital Tarang Agarwal - Old Bridge Capital Kunal Dhamesha - Macquarie Darshan Jhaveri - Crown Capital Madhav Marda - FIS International Operator Ladies and gentlemen, good day and welcome to the Dr. Reddy's Q1 FY 2023 Earnings Conference Call. As a reminder, all participant lines will be in listen-only mode.

Dr. Reddy's Laboratories Limited's (RDY) CEO Erez Israeli on Q1 2023 Results - Earnings Call Transcript

Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.

Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Alcon--Dr. Reddy's Laboratories Ltd. today announced that it has entered into a licensing agreement with Princeton, New Jersey based Slayback Pharma LLC.

Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.

HYDERABAD, India & PRINCETON, NJ--(BUSINESS WIRE)---- $RDY #Bortezomib--Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market.

Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's announces the first-to-market launch of over-the-counter, store-brand equivalent of Allegra-D® 24 HR in the U.S. Market.

Dr. Reddy's Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

HYDERABAD, India &PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories announces the launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. market.

Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market

BENGALURU, India--(BUSINESS WIRE)-- #Aurigene--The collaboration combines Aurigene's small molecule drug discovery platform and EQRx's pioneering business model to accelerate the development of drug candidates in the areas of oncology and immune-inflammatory diseases and improve global access to innovative medicines. Under the terms of the collaboration agreement, Aurigene and EQRx will collaborate on drug discovery, pre-clinical and clinical development and commercialization. Aurigene will lead drug disco

Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Acquisition--Dr. Reddy's Laboratories Ltd. today announced that it has acquired a portfolio of branded and generic injectable products from Eton Pharmaceuticals.

Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #BayerHealthCare--Dr. Reddy's Laboratories announces the launch of the generic version of Nexavar (sorafenib) Tablets, USP, 200 mg in the U.S. market.

Dr. Reddy's Laboratories announces the launch of the generic version of Nexavar (sorafenib) Tablets, USP, 200 mg in the U.S. market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #ALIMTA--Dr. Reddy's Laboratories announces the launch of Pemetrexed for Injection USP, in the U.S. Market

Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market

Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.

Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q4 2022 Earnings Conference Call May 19, 2022 8:00 AM ET Company Participants Amit Agarwal - Head of Investor Relations and Director of Finance Gunupati Prasad - Co-Chairman & Managing Director Erez Israeli - Chief Executive Officer Parag Agarwal - Chief Financial Officer Conference Call Participants Kunal Dhamesha - Macquarie Neha Manpuria - Bank of America Surya Patra - Philip Capital Nikhil Mathur - HDFC Mutual Fund Prakash Agarwal - Axis Capital Sameer Baisiwala - Morgan Stanley Vishal Manchanda - Nirmal Bang Nitin Agarwal - DAM Capital Vinod B - InCred Capital Operator Ladies and gentlemen, good day and welcome to the Q4 FY '22 Earnings Conference Call of Dr. Reddy's Laboratories Limited. [Operator Instructions] Please note that this conference is being recorded.

Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q4 2022 Results - Earnings Call Transcript

Alibaba

Banco Bradesco

Baidu

ICICI Bank Ltd.

Infosys

JD.com

NetEase

Sasol

Grupo Televisa, S.A.B.

Right now, it's easy to be down on the global stock market. While the U.S. market is off about 7% so far in 2022, emerging market stocks are about 10% lower than where they were to start the year.

11 Emerging Market Stocks That Analysts Love

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- #DRREDDY--Dr. Reddy's Laboratories announces the launch of Posaconazole Delayed-Release Tablets in the U.S. Market.

News for Dr. Reddy's Labs Stock (RDY)